World of Showjumping

This week

Coming weeks

CSI5*/CSI2* Calgary - ...

CSIO5*/CSI3*/CSI2* Knokke

CSI4*/CSI2* Valkenswaard
The Netherlands

CSI3* Tryon

CSI3* Sariego

CSI3* Traverse City

CSI3* Ommen
The Netherlands

CSI2* Peelbergen
The Netherlands

CSI2* Vilamoura

CSI2* Montefalco

CSI2* Courriére

FEI Tribunal issues Final Decision in human anti-doping case

Sunday, 12 May 2019


Press release from FEI 



The FEI Tribunal has issued its Final Decision in a human anti-doping case involving an adverse analytical finding for the prohibited substance Boldenone and a metabolite. Boldenone is a non-specified substance on the World Anti-Doping Agency (WADA) List.

A sample taken from the El Salvadoran athlete Paulo Sergio Mateo Santana Filho (FEI ID 10027830/ESA) on 9 June 2018 during the CSI5* Calgary, Spruce Meadows (CAN) returned positive to the two substances. The athlete was notified of the violation of the FEI’s Anti-Doping Rules for Human Athletes (ADRHA) on 11 July 2018. He was provisionally suspended from the date of notification.

In the Final Decision, and in accordance with Article 169 of the FEI General Regulations and Article 10 of the ADRHA, the athlete has been suspended for a period of four years, the standard sanction for non-specified substances. The period of provisional suspension, effective from 11 July 2018, has been credited against the period of ineligibility imposed in this decision, meaning that the athlete will be ineligible until 10 July 2022.

Additionally, the athlete has been fined CHF 4,000 and ordered to pay costs of CHF 5,000.

The athlete can appeal to the Court of Arbitration for Sport (CAS) within 21 days of receipt of the decision (25 April 2019). The El Salvadoran National Anti-Doping Organisation and WADA may also appeal the decision to CAS within the timeframes set out in Article 13 of the ADRHA.

The full text of the FEI Tribunal’s Final Decision is available here.

This photo has been added to your cart !

Your shopping cart »
This website is using cookies for statistics, site optimization and retargeting purposes. You consent to our cookies if you continue to use this website. Read more here.